title: Effects of insulin and sulphonylureas on insulin-like growth factor-I levels in streptozotocin-induced diabetic rats.
abstract: OBJECTIVE
  Diabetes Mellitus is associated with decreased insulin-like growth factor-I (IGF-I) levels and also, poor growth in diabetes is related with low circulating levels of IGF-I. Insulin acts via an increase of IGF-I synthesis on growth. We studied the effects of insulin and sulphonylureas on serum IGF-I levels and aimed to evaluate the restoration of IGF-I in different therapeutic strategies.
  
  
  METHODS
  Thirty male rats were used in the study and diabetes was induced by a single intraperitoneal injection of streptozotocin (35 mg/kg body weight). After confirmation of hyperglycemia, rats were divided into three groups. The first group was treated with insulin, and second group with glimepiride, third group was not treated (control group). IGF-I levels were measured at basal, after streptozotocin and at the end of the treatment period.
  
  
  RESULTS
  Serum IGF-I levels were found to decrease from 577.2 ng/ml to 253.0 ng/ml after streptozotocin (p<0.005). After 1 month, IGF-1 levels were found 524.0 ng/ml in insulin group, 449.3 ng/ml in sulphonylurea group, and 313.1 ng/ml in control group. The increase in IGF-I was statistically significant in insulin group (p<0.005), and in sulphonylurea group (p<0.05), but it was not significant in control group (p>0.05).
  
  
  CONCLUSIONS
  Serum IGF-I levels decrease in diabetes and insulin treatment restores IGF-I depletion significantly. And although less effective, treatment with glimepiride restores IGF-I levels significantly.
authors.affiliation: Department of Endocrinology, Medical Faculty of Adnan Menderes University, Aydin, TURKEY. enginguney@hotmail.com
authors.forename: Engin
authors.initials: E
authors.lastname: Guney
authors.forename: Gurcan
authors.initials: G
authors.lastname: Kisakol
authors.forename: Aysin
authors.initials: A
authors.lastname: Oge
authors.forename: Candeger
authors.initials: C
authors.lastname: Yilmaz
authors.forename: Taylan
authors.initials: T
authors.lastname: Kabalak
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D004195:Disease Models, Animal; D007328:Insulin / Q000494:pharmacology* / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013453:Sulfonylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D007328:Insulin; D013453:Sulfonylurea Compounds; D007334:Insulin-Like Growth Factor I; C057619:glimepiride